[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE204468T1 - Mittel zur verzögerten freisetzung von menschlichem wachstumshormon - Google Patents

Mittel zur verzögerten freisetzung von menschlichem wachstumshormon

Info

Publication number
ATE204468T1
ATE204468T1 AT96919016T AT96919016T ATE204468T1 AT E204468 T1 ATE204468 T1 AT E204468T1 AT 96919016 T AT96919016 T AT 96919016T AT 96919016 T AT96919016 T AT 96919016T AT E204468 T1 ATE204468 T1 AT E204468T1
Authority
AT
Austria
Prior art keywords
composition
hgh
biologically active
sustained release
polymer
Prior art date
Application number
AT96919016T
Other languages
English (en)
Inventor
Olufunmi Lily Johnson
Medha M Ganmukhi
Howard Bernstein
Henry Auer
M Amin Khan
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/473,544 external-priority patent/US5654010A/en
Application filed by Alkermes Inc filed Critical Alkermes Inc
Application granted granted Critical
Publication of ATE204468T1 publication Critical patent/ATE204468T1/de

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT96919016T 1995-06-07 1996-06-03 Mittel zur verzögerten freisetzung von menschlichem wachstumshormon ATE204468T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/473,544 US5654010A (en) 1992-12-02 1995-06-07 Composition for sustained release of human growth hormone
US08/477,725 US5667808A (en) 1992-12-02 1995-06-07 Composition for sustained release of human growth hormone
PCT/US1996/008086 WO1996040072A2 (en) 1995-06-07 1996-06-03 Composition for sustained release of human growth hormone

Publications (1)

Publication Number Publication Date
ATE204468T1 true ATE204468T1 (de) 2001-09-15

Family

ID=27044171

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96919016T ATE204468T1 (de) 1995-06-07 1996-06-03 Mittel zur verzögerten freisetzung von menschlichem wachstumshormon

Country Status (22)

Country Link
EP (1) EP0831787B1 (de)
JP (1) JPH11506740A (de)
CN (1) CN1102854C (de)
AT (1) ATE204468T1 (de)
AU (1) AU708756B2 (de)
BR (1) BR9608542A (de)
CA (1) CA2223436A1 (de)
CZ (1) CZ288147B6 (de)
DE (1) DE69614685T2 (de)
DK (1) DK0831787T3 (de)
ES (1) ES2161366T3 (de)
HK (1) HK1009089A1 (de)
HU (1) HUP9900870A3 (de)
IL (1) IL122385A (de)
MX (1) MX9709698A (de)
NO (1) NO316104B1 (de)
NZ (1) NZ310644A (de)
PL (1) PL184531B1 (de)
PT (1) PT831787E (de)
RU (1) RU2161502C2 (de)
SK (1) SK281571B6 (de)
WO (1) WO1996040072A2 (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6242096A (en) * 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. Method of producing sustained-release preparation
CA2275422A1 (en) * 1996-12-20 1998-07-02 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
AR012448A1 (es) * 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
EP2050762A3 (de) 1998-03-10 2009-07-08 Genentech, Inc. Neue Polypeptide und für diese kodierende Nukleinsäuren
EP3112468A1 (de) 1998-05-15 2017-01-04 Genentech, Inc. Il-17-homologe polypeptide und therapeutische verwendung davon
JP3577586B2 (ja) 1998-05-15 2004-10-13 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療用途
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
EP1953173B1 (de) 1999-06-15 2009-11-18 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
CA2490853A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1897946B1 (de) 1999-12-23 2012-07-11 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
KR20080006002A (ko) 2000-01-13 2008-01-15 제넨테크, 인크. 신규 Ｓｔｒａ6 폴리펩티드
US6740520B2 (en) 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
AU4935701A (en) 2000-03-24 2001-10-08 Genentech Inc Use of insulin for the treatment of cartilagenous disorders
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE60136281D1 (de) 2000-08-24 2008-12-04 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (de) 2000-09-01 2008-09-17 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
WO2002053136A1 (fr) 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Preparations a liberation soutenue
US7271150B2 (en) 2001-05-14 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
PT1397155E (pt) 2001-06-21 2015-12-07 Genentech Inc Formulação de libertação sustentada
CA2477249A1 (en) 2002-02-25 2003-09-04 Genentech, Inc. Novel type-1 cytokine receptor glm-r
HUE030579T2 (en) 2003-04-04 2017-05-29 Genentech Inc High Concentration Antibody And Protein Products
DK1636593T5 (da) 2003-06-06 2009-07-27 Genentech Inc Modulering af vekselvirkningen mellem HGF-beta-kæde og c-met
ES2751414T5 (es) 2003-07-08 2024-04-23 Novartis Pharma Ag Anticuerpos antagonistas a polipéptidos heterólogos IL-17 A/F
EP1692178A1 (de) 2003-12-11 2006-08-23 Genentech, Inc. Verfahren und produkt um c-met dimerisierung und aktivierung zu verhindern
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
AU2005229434B2 (en) 2004-03-30 2010-09-30 Nsgene A/S Therapeutic use of a growth factor, NsG33
KR101242543B1 (ko) 2004-10-27 2013-03-22 유니버시티 오브 덴버 부신피질 자극 호르몬 유사체 및 관련 방법
AU2005314426A1 (en) 2004-12-10 2006-06-15 Talima Therapeutics, Inc. Compositions and methods for treating conditions of the nail unit
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
AU2006255686A1 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
WO2008018854A2 (en) 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
KR101502920B1 (ko) 2005-06-21 2015-03-17 조마 (유에스) 엘엘씨 ＩＬ-１β 결합성 항체 및 그의 단편
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
JP2009504183A (ja) 2005-08-15 2009-02-05 ジェネンテック・インコーポレーテッド 遺伝子破壊、それに関連する組成物および方法
CN101297034A (zh) 2005-08-24 2008-10-29 洛克菲勒大学 Ply-gbs突变溶素
US20090293137A1 (en) 2005-11-21 2009-11-26 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
NZ568809A (en) 2005-12-22 2011-08-26 Genentech Inc Recovering and purification of VEGF proteins from prokaryotic cells using polyanionic agents
ZA200807714B (en) 2006-02-17 2010-01-27 Genentech Inc Gene disruptions, compositions and methods relating thereto
KR20080110810A (ko) 2006-03-23 2008-12-19 노파르티스 아게 항-종양 세포 항원 항체 치료제
CN103351425B (zh) 2006-04-10 2016-01-20 健泰科生物技术公司 散乱蛋白pdz调节剂
AU2007297565A1 (en) 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
BRPI0716261A2 (pt) * 2006-08-31 2013-08-06 Novartis Ag composiÇÕes farmacÊuticas compreendendo hch para distribuiÇço oral
CA2673592C (en) 2006-12-20 2014-03-25 Xoma Technology Ltd. Methods for the treatment of il-1.beta. related diseases
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
MX2010001684A (es) * 2007-08-15 2010-04-21 Amunix Inc Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
DK2391650T3 (en) 2007-12-20 2015-01-12 Xoma Us Llc Methods of treating gout
GB0812742D0 (en) 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
JP6016636B2 (ja) 2009-10-15 2016-10-26 ジェネンテック， インコーポレイテッド 改変したレセプター特異性を持つキメラ線維芽細胞増殖因子
US8771693B2 (en) 2009-10-27 2014-07-08 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
JP5878477B2 (ja) 2010-01-15 2016-03-08 ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー 骨の治癒を加速するためのバナジウム化合物の使用
CA2792125C (en) 2010-03-22 2019-02-12 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
JP2013525484A (ja) 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
CA3111727C (en) 2010-06-24 2022-07-26 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
JP6149226B2 (ja) 2010-10-01 2017-06-21 ホーバ セラピューティクス アンパルトセルスカブ アロディニア、痛覚過敏、自発痛及び幻肢痛の処置
KR101687060B1 (ko) 2010-10-08 2016-12-15 상하이 켁신 바이오테크 씨오., 엘티디. 모에신 조절제 및 그의 용도
US9345765B2 (en) 2010-10-08 2016-05-24 Shanghai Kexin Biotech Co., Ltd. Diagnostic and therapeutic uses of moesin fragments
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
CN102875683B (zh) * 2011-07-11 2014-06-11 旭华（上海）生物研发中心有限公司 长效重组人生长激素的Fc融合蛋白
WO2013066866A1 (en) 2011-10-31 2013-05-10 Genentech, Inc. Antibody formulations
EP3050900A1 (de) 2011-12-19 2016-08-03 Xoma (Us) Llc Verfahren zur behandlung von akne
AU2013208003B2 (en) 2012-01-09 2017-12-14 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
JP2015509091A (ja) 2012-01-09 2015-03-26 ザ スクリプス リサーチ インスティテュート ヒト化抗体
CA2904703A1 (en) 2013-03-14 2014-10-02 Hallux, Inc. Method of treating infections, diseases or disorders of nail unit
ES2835716T3 (es) 2013-03-15 2021-06-23 Beth Israel Deaconess Medical Ct Inc Procedimientos y composiciones para la generación y el uso de anticuerpos específicos de conformación
US20160168231A1 (en) 2013-07-18 2016-06-16 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
CN105814074B (zh) 2013-07-18 2020-04-21 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
EP3043824B1 (de) 2013-09-13 2022-07-06 The Scripps Research Institute Modifizierte therapeutische mittel und zusammensetzungen daraus
KR102339240B1 (ko) 2013-10-15 2021-12-15 더 스크립스 리서치 인스티튜트 펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
US20150238631A1 (en) 2013-10-15 2015-08-27 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
CN104623639A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 白介素22二聚体在制备治疗胰腺炎药物中的应用
CA2931547A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
NL2014230B1 (en) 2015-02-04 2016-10-12 Stichting Vu-Vumc Wound healing formulation.
MA41629A (fr) 2015-03-04 2018-01-09 Center For Human Reproduction Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
EP3310376A4 (de) 2015-06-17 2019-01-23 The California Institute for Biomedical Research Modifizierte therapeutische mittel und zusammensetzungen daraus
EP3442562B1 (de) 2016-04-15 2022-09-21 Evive Biotechnology (Shanghai) Ltd Ein il-22-dimer zur verwendung in der behandlung der nekrotisierenden enterokolitis
JP7149935B2 (ja) 2016-10-19 2022-10-07 ザ スクリプス リサーチ インスティテュート ヒト化された標的化部分および／または最適化されたキメラ抗原受容体相互作用ドメインを有する、キメラ抗原受容体エフェクター細胞スイッチ、ならびにその使用
EP3946457A1 (de) 2019-04-01 2022-02-09 Genentech, Inc. Zusammensetzungen und verfahren zur stabilisierung von proteinhaltigen formulierungen
US12098212B2 (en) 2019-08-12 2024-09-24 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
JP2022554187A (ja) 2019-10-24 2022-12-28 ミノトール セラピューティクス インコーポレイテッド キメラサイトカイン改変抗体およびその使用方法
CA3217865A1 (en) 2021-04-28 2022-11-03 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
AU2022269279A1 (en) 2021-05-06 2023-11-30 Hoba Therapeutics Aps Prevention and treatment of chemotherapy-induced neuropathic pain
EP4444338A1 (de) 2021-12-10 2024-10-16 Hoba Therapeutics ApS Behandlung von nozizeptivem schmerz

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
JPH08503950A (ja) * 1992-12-02 1996-04-30 アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド 徐放性成長ホルモン含有マイクロスフェア
CN1157562A (zh) * 1994-09-09 1997-08-20 武田药品工业株式会社 含有一种肽金属盐的缓释制剂

Also Published As

Publication number Publication date
HUP9900870A2 (hu) 1999-09-28
DE69614685D1 (de) 2001-09-27
PL323832A1 (en) 1998-04-27
AU6146996A (en) 1996-12-30
PL184531B1 (pl) 2002-11-29
EP0831787A2 (de) 1998-04-01
PT831787E (pt) 2002-02-28
SK167197A3 (en) 1998-06-03
CZ390797A3 (cs) 1998-07-15
NZ310644A (en) 1999-08-30
DE69614685T2 (de) 2002-06-27
NO975708D0 (no) 1997-12-05
EP0831787B1 (de) 2001-08-22
ES2161366T3 (es) 2001-12-01
CA2223436A1 (en) 1996-12-19
IL122385A (en) 2001-01-11
SK281571B6 (sk) 2001-05-10
WO1996040072A2 (en) 1996-12-19
JPH11506740A (ja) 1999-06-15
NO975708L (no) 1998-02-05
DK0831787T3 (da) 2001-12-17
CN1102854C (zh) 2003-03-12
HUP9900870A3 (en) 2001-04-28
IL122385A0 (en) 1998-06-15
CN1187120A (zh) 1998-07-08
MX9709698A (es) 1998-07-31
WO1996040072A3 (en) 1997-01-23
HK1009089A1 (en) 1999-09-10
NO316104B1 (no) 2003-12-15
RU2161502C2 (ru) 2001-01-10
CZ288147B6 (en) 2001-05-16
BR9608542A (pt) 1999-11-30
AU708756B2 (en) 1999-08-12

Similar Documents

Publication Publication Date Title
ATE204468T1 (de) Mittel zur verzögerten freisetzung von menschlichem wachstumshormon
MX9709699A (es) Composicion para la liberacion sostenida de eritropoyetina no agregada.
DE3853853T2 (de) Verabreichungsformen für Pharmaka.
CA2474698A1 (en) Polymer-based compositions for sustained release
ATE228832T1 (de) System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
WO2001043749A3 (en) Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
DE69840495D1 (de) Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben
WO2001058474A3 (en) Microencapsulation and sustained release of biologically active agent
JPH07187994A (ja) 薬物放出制御製剤
EP1570823A3 (de) Analgetisch wirksame Zusammensetzung mit verzögerter Wirkstoffabgabe von Buprenorphin
ATE433318T1 (de) Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
ATE260651T1 (de) Pharmazeutische ciclosporin-formulierung mit verbesserten biopharmazeutischen eigenschaften, erhöhter physikalischer qualität & stabilität sowie verfahren zur herstellung
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
UA29563C2 (uk) Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду
ATE315409T1 (de) Verbesserte formulierung zur gesteuerten arzneistofffreisetzung durch kombination hydrophiler und hydrophober stoffe
DE3850823D1 (de) System zur Freisetzung von Medikamenten und dessen Herstellungsmethode.
US5342622A (en) Subdermal biocompatible implants
AU7004194A (en) Drug system
SK138096A3 (en) Collagen preparation for the controlled release of active substances
ATE282406T1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
DE19850517B4 (de) Verwendung eines wirkstoffhaltigen transdermalen therapeutischen Systems in einer Kombinationsbehandlung mit und ohne Ultraschall
KR20200099901A (ko) 피나스테라이드를 포함하는 마이크로 입자를 함유한 피하 주사용 조성물
RU97115937A (ru) Применение изосорбид-5-мононитрата

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee